Non-commercial clinical trials (Investigator initiated trials (IIT), - PowerPoint PPT Presentation

Non-commercial clinical trials (Investigator initiated trials (IIT), research-lead trials) Introduction Introduction IIT/TOS IIT/TOS Impact of EU Directive Impact of EU Directive • Definition according to the EU draft guidance Initiation of INTERFANT 06 Initiation of INTERFANT 06 on the specific modalities of „non-commercial Preparation of submission Preparation of submission Application to BfArm Application toBfArm clinical trials“ (2005): Application to EC Application to EC Remarks by the BfArM Specific aspects in TOS “Non-commercial clinical trials” are clinical trials Concerns by the ECs Conclusions and questions conducted by researchers without the participation Specific aspects in TOS Conclusions and questions of the pharmaceutical industry... • “Non-commercial sponsors commonly study the “effectiveness” of a medicinal product compared to alternatives … ”

Characteristics and track record of therapy optimisation studies in paediatric oncology (oncTOS) Introduction Introduction IIT/TOS IIT/TOS Impact of EU Directive Impact of EU Directive • Comparative testing of the effectiveness of standard Initiation of INTERFANT 06 Initiation of INTERFANT 06 Preparation of submission Preparation of submission therapies Application to BfArm Application to BfArm Application to EC Application to EC • Use of authorised medicinal products (authorisation Remarks by the BfArM Specific aspects in TOS often does not cover all ages) Concerns by the ECs Conclusions and questions Specific aspects in TOS • Usually study of treatment concepts (including risk Conclusions and questions stratification), no single drugs • Patient recruitment by a large number of study sites in order to ensure nation-wide coverage • Limited financial resources (non-industrial funding) • Standard care in paediatric oncology for >30 years • Surveillance by Data Safety and Monitoring Committees • Extensive progress in treatment results and non-clinical research through international cooperations

EU Clinical Trials Directive Official Goals • Improve protection of patients and reliabilty of research Introduction Introduction IIT/TOS IIT/TOS reporting Impact of EU Directive Impact of EU Directive • Harmonise and increase the competitiveness of Initiation of INTERFANT 06 Initiation of INTERFANT 06 Preparation of submission Preparation of submission European clinical research Application to BfArm Application to BfArm Application to EC Application to EC � Changes concern non-commercial as well as Remarks by the BfArM Specific aspects in TOS pharmaceutical industry clinical trials Concerns by the ECs Conclusions and questions Specific aspects in TOS Conclusions and questions • If investigational medicinal products (IMPs) with marketing authorisation are used, some simplifications were realized for non-commercial clinical trials regarding – access to the IMPs – IMP-related data (SmPC instead of IMP Dossier) – labelling of the IMPs – documentation

EU Clinical Trials Directive Consequences Introduction IIT/TOS • More requirements regarding Impact of EU Directive – procedure of approval by authorities and ethical Initiation of INTERFANT 06 Preparation of submission committees Application to BfArm – trial insurance Application to EC Remarks by the BfArM – quality assurance and quality control Concerns by the ECs – pharmacovigilance Specific aspects in TOS Conclusions and questions – validation of data acquisition systems – data archiving � resulting in higher administrative efforts and costs

Effect of the EU Directive on trial initiation Introduction IIT/TOS • EORTC:* Impact of EU Directive – new trials in 2004: n=19, in 2005: n=7 Initiation of INTERFANT 06 Preparation of submission – increase of trial costs by 85% Application to BfArm Application to EC – increase of insurance costs from 70,000 € to Remarks by the BfArM 140,000 € Concerns by the ECs Specific aspects in TOS – trial initiation ~5 months slower Conclusions and questions • Ethics committee in Helsinki:* – new IIT in 2003: n=20, in 2005: n=5 – protocol amendments in 2003 n=18, in 2005: n=69 • GPOH: – new trials: 2002 - Apr. 2004: n=14 May 2004 - 2007: n=2 *Hemminki et al, BMJ, 2006

Initiation procedure of INTERFANT 06 in Germany Preparation of submission to authorities and ethics committees Introduction IIT/TOS Impact of EU Directive • Finalisation of the German protocol part Initiation of INTERFANT 06 � size of the complete final protocol version: 317 pages Preparation of submission Application to BfArm (including SmPCs) (INTERFANT 99: 150 pages) Application to EC Remarks by the BfArM • Patient information: 18 pages (INTERFANT 99: 4 pages) Concerns by the ECs Specific aspects in TOS • Collection of the qualification documents of study clinics (n=47) Conclusions and questions and investigators (n=150); documents complete about one year later � ~1000 pages • [Application to the Deutsche Krebshilfe for funding (~9 months)] • Attempt to conclude the trial insurance using the inexpensive master policy of the German Cancer Association failed because SCT is included in the protocol (although all pts. undergoing SCT (estimated no. per year: 2-3) will in fact enter trial ALL-SZT BFM 2003). � Costs for 65 patients: 27.887,- € (instead of 1980,- €)

Initiation procedure of INTERFANT 06 in Germany Submission to the authorities Introduction • Submission of the protocol to the authorities IIT/TOS (15.01.08): Impact of EU Directive Initiation of INTERFANT 06 – authority primarily concerned: Bundesinstitut für Preparation of submission Arzneimittel und Medizinprodukte (BfArM) Application to BfArm Application to EC – Paul-Ehrlich-Institut (competent authority for clinical Remarks by the BfArM trials with sera, blood products...) also involved Concerns by the ECs Specific aspects in TOS (hematopoietic stem cells, ATG) Conclusions and questions • Submitted documents: – Application form Module 1 (315 pages) – Trial protocol (317 pages) x 4 – some other documents � Submission of ~2560 pages • all administered drugs (supportive therapy excluded) were regarded as investigational medicinal products (IMPs) � 28 IMPs (considering different pharmaceutical forms)

Initiation procedure of INTERFANT 06 in Germany Submission to the Ethics Committees Introduction IIT/TOS • Submission of the protocol to the ethics committees (EC) Impact of EU Directive (15.01.08): Initiation of INTERFANT 06 Preparation of submission – EC in charge (Kiel) � for 47 trial sites Application to BfArm – 35 involved EC Application to EC Remarks by the BfArM • Charges by the involved EC: 0,- to 1300,- € � ~ 6000,- € Concerns by the ECs Specific aspects in TOS • Submitted documents: Conclusions and questions – Application form Module 1 (315 pages) – Application form Module 2 (8 pages) x 79 – Trial protocol (317 pages) – some other documents (18 pages) – investigator/trial site qualification docs (3000 pages) � ~ 55,000 pages • + 36 CD-ROMs (1 per EC)

Submission of a TOS to the Ethics Committees 1999 2008

Initiation procedure of INTERFANT 06 in Germany Remarks by the BfArM (and PEI) Introduction IIT/TOS • Initial formal complaints (corrected by 18.02.08): Impact of EU Directive Initiation of INTERFANT 06 – „Complete documents have to be submitted Preparation of submission Application to BfArm regarding production and application of the stem Application to EC cells.“ Remarks by the BfArM Concerns by the ECs – „A statement is required, why the study shall recruit Specific aspects in TOS underage patients.“ (According to the AMG the Conclusions and questions conduction of a clinical trial in underage patients is only allowed if sufficient results can not be expected when conducting the trial in adult patients ... ) – German label for the drug Erwinase was required. • Still waiting for the final approval...

Initiation procedure of INTERFANT 06 in Germany Concerns by the Ethics Committees Introduction IIT/TOS Major concerns regarding Impact of EU Directive Initiation of INTERFANT 06 – Patient information Preparation of submission Application to BfArm • insurance Application to EC Remarks by the BfArM • data exchange Concerns by the ECs Specific aspects in TOS • drug side effects Conclusions and questions – Preservation of left-over specimens for future research – Data protection

Data protection: Specific aspects in oncological TOS Introduction • OncTOS include standard patient care, quality IIT/TOS Impact of EU Directive assurance, and research. Initiation of INTERFANT 06 • Germany, G-BA (=Gemeinsamer Bundesausschuß, Preparation of submission Application to BfArm Common Federal Committee of physicians and health Application to EC insurance companies): „Agreement for Paediatric Remarks by the BfArM Oncology“ requires participation in TOS. Concerns by the ECs Specific aspects in TOS • In general, „trial-related“ diagnostics and treatment Conclusions and questions represent the best available standard for that disease entity. • Reference laboratories provide results which are relevant for – treatment of the individual patient – research • Study center is concerned with – medical consultation of the clinicians – central risk stratification – trial execution (e.g. data collection, randomization)